Advanced Biomed

Advanced Biomed Payables Turnover

The Payables Turnover Ratio of Advanced Biomed (ADVB) as of Nov 5, 2026 is 0.49. In the previous year, Payables Turnover Ratio was 0.02 — a change of 2,345.08% (higher).

Payables Turnover

0.49

YoY

2,345.08%

Last updated:

Payables Turnover Ratio of Advanced Biomed is 2025 0.49 . Payables Turnover Ratio of Advanced Biomed was 2024 0.02 . It decreases by 2,345.08% higher compared to the previous year.

The Advanced Biomed Payables Turnover history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Payables Turnover
Date
Payables Turnover
Jan 1, 2021
10.47 USD
Jan 1, 2022
0.01 USD
Jan 1, 2023
0.02 USD
Jan 1, 2024
0.02 USD
Jan 1, 2025
0.49 USD
The Advanced Biomed Payables Turnover history
YEARPayables TurnoverYoY
0.49+2,345.08%
0.02+7.65%
0.02+219.88%
0.01-99.94%
10.47—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Advanced Biomed Stock analysis

What does Advanced Biomed do? Advanced Biomed, Inc. generates revenue through the sale of assay products and services for cancer patients, including early screening, diagnosis, staging, treatment selection, and patient outcome interventions. The company's microfluidic technology platform integrates R&D, design, and manufacturing of biochips, leveraging patented chip technology and semiconductor-based biosensors. Key products include the A+Pre, AC-1000, A+CellScan, and A+SCDrop devices, paired with corresponding microfluidic biochips such as A+Pre-Chip, AC-1000 CTC Enrichment Chip, and A+CellScan Chip, which are sold to healthcare providers and research institutions. The company targets healthcare providers and research institutions seeking advanced diagnostic tools for cancer care. Its microfluidic platform enables localized operations of various microfluidic chips and biosensors, supporting applications in early cancer detection and personalized treatment strategies. Revenue streams are derived from both device sales and service offerings, with a focus on integrating semiconductor fabrication technology into medical diagnostics. Advanced Biomed's product portfolio centers on biochip-based solutions for cancer diagnostics, with devices like A+Pre and AC-1000 designed for specific clinical applications. The firm's revenue model combines the sale of proprietary devices and biochips with service-based interventions, ensuring comprehensive support for cancer patient management from screening to treatment outcomes. Healthcare providers and research institutions are the primary buyers of these integrated diagnostic solutions. Advanced Biomed is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Advanced Biomed stock

Payables Turnover Ratio of Advanced Biomed is 0.49 in 2025.

Payables Turnover Ratio of Advanced Biomed changed from 0.02 to 0.49, representing a 2,345.08% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Payables Turnover Ratio Advanced Biomed since 2006 – with annual values, charts, and detailed analysis.

Payables turnover measures how quickly a company pays its suppliers. Lower turnover may indicate better payment terms or cash flow management.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Payables Turnover Ratio's Advanced Biomed with sector peers and the industry average to assess whether it is attractive.

To evaluate Payables Turnover Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Payables Turnover Ratio.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Advanced Biomed

All Key Metrics — Advanced Biomed